116 related articles for article (PubMed ID: 26685496)
1. Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations.
Bryson E; Hartman R; Arnold J; Gorman G; Sweitzer S; Asbill S
Int J Pharm Compd; 2015; 19(2):161-6. PubMed ID: 26685496
[TBL] [Abstract][Full Text] [Related]
2. Skin permeation and antinociception of topical gabapentin formulations.
Bryson E; Asbill S; Sweitzer S
Int J Pharm Compd; 2014; 18(6):504-11. PubMed ID: 25906628
[TBL] [Abstract][Full Text] [Related]
3. Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel.
Woodall R; Arnold JJ; McKay D; Asbill CS
Int J Pharm Compd; 2013; 17(3):247-53. PubMed ID: 24046940
[TBL] [Abstract][Full Text] [Related]
4. In vitro skin penetration and skin content of progesterone from various topical formulations.
Heustess A; Asbill S; Eagerton D; Arnold J
Int J Pharm Compd; 2014; 18(6):512-5. PubMed ID: 25906629
[TBL] [Abstract][Full Text] [Related]
5. Compounded Topical Amitriptyline for Neuropathic Pain: In Vitro Release from Compounding Bases and Potential Correlation with Clinical Efficacy.
Shakshuki A; Yeung P; Agu RU
Can J Hosp Pharm; 2020; 73(2):133-140. PubMed ID: 32362670
[TBL] [Abstract][Full Text] [Related]
6. Impact of the chemical and physical stability of ketoprofen compounded in various pharmaceutical bases on its topical and transdermal delivery.
Nornoo AO; Wulz J; Yoon H; Nan Y; Lese M
Pharm Dev Technol; 2016 Mar; 21(2):204-13. PubMed ID: 25431959
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Transdermal Drug Permeation as Modulated by Lipoderm and Pluronic Lecithin Organogel.
Zhang Q; Song Y; Page SW; Garg S
J Pharm Sci; 2018 Feb; 107(2):587-594. PubMed ID: 28935590
[TBL] [Abstract][Full Text] [Related]
8. Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time.
Heustess A; Spigener S; Sweitzer S; Romero-Sandoval A; Asbill S
Int J Pharm Compd; 2015; 19(2):167-73. PubMed ID: 26685497
[TBL] [Abstract][Full Text] [Related]
9. The release and transdermal penetration of baclofen formulated in a poloxamer lecithin organogel.
Arnold JJ; Asbill S
Int J Pharm Compd; 2009; 13(6):569-71. PubMed ID: 23965331
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model.
Baneshi M; Tyagi D; Panneerselvam E; MacKenzie G; Coleman J; Zhang SX
Int J Pharm Compd; 2023; 27(5):424-430. PubMed ID: 37816184
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the percutaneous absorption of promethazine hydrochloride, in vitro, using the human ex vivo skin model.
Bassani AS; Banov D; Lehman PA
Int J Pharm Compd; 2008; 12(3):270-3. PubMed ID: 23969717
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
Bassani AS; Banov D
Pain Med; 2016 Feb; 17(2):230-8. PubMed ID: 26352507
[TBL] [Abstract][Full Text] [Related]
13. Intranasal delivery of cyclobenzaprine hydrochloride-loaded thiolated chitosan nanoparticles for pain relief.
Patel D; Naik S; Chuttani K; Mathur R; Mishra AK; Misra A
J Drug Target; 2013 Sep; 21(8):759-69. PubMed ID: 23879335
[TBL] [Abstract][Full Text] [Related]
14. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone.
Toth PP; Urtis J
Clin Ther; 2004 Sep; 26(9):1355-67. PubMed ID: 15530999
[TBL] [Abstract][Full Text] [Related]
15. Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs.
Gorman G; Sokom S; Coward L; Arnold JJ
Int J Pharm Compd; 2017; 21(2):164-170. PubMed ID: 28346213
[TBL] [Abstract][Full Text] [Related]
16. Determination of Degradation Products of Cyclobenzaprine Hydrochloride, Lidocaine and Piroxicam in a Semi-Topical Formulation: MS-MS Confirmation of Unknown Impurities.
Cioroiu BI; Grigoriu IC; Cioroiu ME; Niculaua M; Lupuleasa R; Lazar MI
J Chromatogr Sci; 2016 Jul; 54(6):902-11. PubMed ID: 27056018
[TBL] [Abstract][Full Text] [Related]
17. Treatment of levator ani syndrome with cyclobenzaprine.
Sheikh M; Kunka CA; Ota KS
Ann Pharmacother; 2012 Oct; 46(10):e29. PubMed ID: 22991133
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.
Darwish M; Hellriegel ET
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1425-36. PubMed ID: 20883117
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
Darwish M; Hellriegel ET
Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
[TBL] [Abstract][Full Text] [Related]
20. Compounded pain formulations: what is the evidence?
Asbill S; Sweitzer SM; Spigener S; Romero-Sandoval A
Int J Pharm Compd; 2014; 18(4):278-86. PubMed ID: 25474856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
